Nattawat Klomjit, MD, highlights key advancements in complement inhibitors presented at ASN Kidney Week 2024, particularly in glomerular disease treatment. The VALIANT trial presented compelling results with pegcetacoplan, showing a 68% reduction in proteinuria and a 6.3 mL/min eGFR improvement in patients with C3 glomerulopathy.
Dr Klomjit also notes iptacopan's impact in IgA nephropathy from the APPLAUSE-IgAN trial, where the drug reduced proteinuria by 38% and decreased complement activation markers. Additionally, the APPEAR-C3G trial demonstrated iptacopan's success in reducing proteinuria by 37% in patients with C3G, marking an exciting development in complement blockade therapy.
Medscape © 2024 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: ASN 2024: Key Highlights in the Treatment of Glomerular Disease - Medscape - Oct 31, 2024.
Comments